Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.
Depressed outpatients (n = 51) resistant to treatment with maprotiline were treated in a blind, randomized, single-centre study, for 6 weeks with either the reversible and selective monoamine oxidase A-inhibitor (MAO-A-I), brofaromine or lithium addition to maprotiline. The Hamilton Rating Scale for Depression was scored by an independent rater before and after the 6 week treatment period. No significant differences in efficacy were found between the two treatment regimes. In the patients who completed the trial, brofaromine was well tolerated with the exception of insomnia. Anticholinergic effects as well as thyroid dysfunctions (17 out of 20) were more frequent in the maprotiline/lithium group.
Hoencamp
E
E
Psychiatric Center Bloemendaal, The Hague, The Netherlands.
Haffmans
P M
PM
Dijken
W A
WA
Hoogduin
C A
CA
Nolen
W A
WA
van Dyck
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008376:Maprotiline / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D010555:Personality Inventory; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012008:Recurrence
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; D008376:Maprotiline; C038213:brofaromine; D008094:Lithium